EI
CSCI

EAM Investors’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

EAM Investors’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,710
Closed -$795K – 322
2019
Q1 		$795K Buy
+1,710
New +$664K 0.2% 206

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's CSCI Position: Q2 2019 in Review

EAM Investors sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q2 2019, closing a stake of 1,710 shares — an estimated $795K sold.

EAM Investors first reported a position in CSCI in Q1 2019 and held it in 1 quarter. The position peaked at $795K in Q1 2019. 26 funds tracked by Wall St. Rank hold CSCI as of Q2 2019.

  • EAM Investors reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • EAM Investors sold 1,710 COSCIENS Biopharma Inc. Common Stock shares in Q2 2019, an estimated $795K.
  • EAM Investors first reported a position in COSCIENS Biopharma Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • EAM Investors's COSCIENS Biopharma Inc. Common Stock position peaked at $795K in Q1 2019.
  • 26 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q2 2019.

Based on EAM Investors's 13F filing for Q2 2019, filed 14 Aug 2019.